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Abstract: 
Daidzein (4′,7-dihydroxylisoflavone), a water-insoluble isoflavone, is mainly present in 
leguminous plants. This study was aimed at investigating the absorption characteristics of 
daidzein across the intestinal membranes. Borneol has been used to enhance the intestinal 
absorption and bioavailability of daidzein. We chose an in vitro diffusion chamber system using 
isolated rat intestinal membranes as a model. A sensitive, accurate and reliable LC method was 
developed and validated to determine daidzein in rat plasma. A linear relationship for daidzein 
was found in the range of 20–800 ng mL−1. The mean absolute recoveries of daidzein determined 
over three concentrations were 89.8 ± 4.8, 91.3 ± 2.8 and 95.4 ± 1.7%. The coefficients of 
variation for inter-day and intra-day assay were found to be less than 6.1%. The plasma 
concentration of daidzin following oral administration was significantly increased by 
coadministration of borneol in rats, and a 1.5-fold enhancement of relative bioavailability of 
daidzein was observed as compared to daidzein administered alone.  
 
Article: 
INTRODUCTION 
Daidzein (Figure 1) (4′,7-dihydroxylisoflavone), a water-insoluble isoflavone, is mainly present 
in leguminous plants, especially in soybeans, soy foods and Pueraria lobata Ohwi (Leguminosae) 
[1, 2]. It has already been demonstrated that diadzein can reduce breast cancer occurrence, and 
may play a key role in protection against colon cancer [3]. More recently, Wilcox and 
Blumenthal [4] have hypothesized that isoflavones might reduce the aggregation of platelets at 
the sites of arterial injury associated with atherosclerotic development [5].  
 
 
 
Figure 1: Structure of daidzein  
Nevertheless, the occurrence of any beneficial effects of bioactive compounds is mainly related 
to their ability to be absorbed in the intestine. Only limited studies on absorption, metabolism, 
and distribution of isoflavones are available [6–11]. Studies of Setchell et al. [12, 13] on 
isoflavone bioavailability in healthy women, showing a curvilinear relationship between dietary 
intake and plasma levels. We focused our attention on intestinal absorption characteristics of 
daidzein because data regarding absorption of this isoflavone are very limited. Borneol, has been 
used in our work to enhance the intestinal absorption and bioavailability of this poorly water-
soluble isoflavone.  
 
Oral administration is the preferred route by virtue of its convenience and better compliance. 
However, the development of this delivery system is considered to be a great challenge due to 
the poor water-solubility, poor permeability and rapid metabolism of some drugs. A variety of 
formulation strategies has been developed to improve the solubility and bioavailability of such 
drugs. Several approaches such as absorption enhancers [14, 15], chemical modification [16, 17] 
and dosage forms [18, 19] have been explored in order to attain peroral delivery of drugs. Of 
these approaches, the use of absorption enhancers has often been adapted to enhance the 
intestinal absorption [15, 20]. Some studies have shown that borneol could improve the oral 
bioavailability of some drugs [21].  
 
In this study, we have investigated the absorption characteristics of daidzein across the intestinal 
membranes. The influence of borneol as an absorption enhancer on the intestinal absorption and 
oral bioavailability of daidzein was also investigated in rats.  
 
EXPERIMENTAL 
Chemicals and Reagents  
Diethyl ether, PEG400, borneol and menthol were purchased from the Shanghai Chemical 
Reagents Institute (Shanghai, China). Daidzein was provided by Qingze Co. (Nanjing, China). 
The purity was 98%, verified using LC.  
 
Chromatographic Conditions  
LC was conducted on Waters (Waters Corp., MA, USA) equipped with 1525 controller pumps, a 
Waters 2487 detector and configured to Millennium 3.2 software. Sample was loaded onto the 
column by means of a Waters 717plus autosampler. Analysis was on an Elite 5 μm C18 column 
(150 × 4.6 mm i.d., Dalian, China). The mobile phase was methanol in distilled deionized water 
(50:50, v/v) at a flow rate 1.0 mL min−1. The analytes were detected at 260 nm.  
 
Preparation of Stock Solutions and Working Solutions  
Stock solutions of daidzein were prepared in methanol (at a concentration of 1 mg mL−1) and 
stored at 4 °C. Plasma samples were stored at −20 °C until required. Working solutions were 
prepared on the day of an analysis by further dilution of the stock solutions with methanol.  
 
Animal Handling  
Healthy male Sprague-Dawley rats (200–250 g) were purchased from the Animal Resources 
Center, Shanghai Jiaotong University, China. Rats were kept in a room under controlled 
temperature (22 ± 1 °C) and automatic day-night rhythm (12 h-cycle) and housed on wire-bottom 
cages with paper underneath. Ethical approval of this study was obtained from the Ethical 
Committees of Shanghai Jiaotong University. Rats were provided with free access to tap water 
and food. After overnight fasting, the animals were anesthetized with diethyl ether. The intestine 
was exposed through a midline abdominal incision, removed, and washed in 0.9% sterile sodium 
chloride solution. Intestinal segments, excluding Peyer’s patches, were isolated and immersed in 
0.9% sterile sodium chloride solution.  
 
Absorption Experiment  
The absorption of daidzein across the rat intestinal membrane was studied with a diffusion 
chamber (Corning Coster Corp.) [22–24]. Segments were cut open and the intestinal sheets were 
mounted onto the pins of the cell, and the half-cells were clamped together. Daidzein solutions 
were freshly prepared by dissolving in DMSO, and were diluted in phosphate buffer solution to 
yield a final concentration of 20 μg mL−1. The final concentration of DMSO in phosphate buffer 
solution was 1% (v/v). Drug solution (7 mL) was added to the donor site, whereas the same 
volume of drug-free buffer was added to the opposite site. The temperature of the intestinal 
membranes was maintained at 37 °C, and both fluids were circulated by gas lift with 95% O2/5% 
CO2. During the absorption studies, aliquots were taken from the receptor chamber at 
predetermined time up to approximately 2 h. The receptor chamber samples were replaced with 
an equal volume of appropriate buffer. The permeated drugs were assayed. The apparent 
permeability coefficients (P app) of the drug were calculated from the slope of the linear portion 
of the permeability-time profiles by the relationship P app = (dX R/dt) × (1/A C0), where P app is 
the apparent permeability coefficient, X R is the amount of drug in the receptor side, A is the 
diffusion area, and C 0 is the initial concentration of drug on the donor side. Efflux ratio was 
used to evaluate the extent of efflux [25–29].  
 
Pharmacokinetic Study  
Eight male Sprague-Dawley rats were fasted overnight with free access to water before drug 
administration. Daidzein was suspended in 20% PEG400 solution as a control sample, borneol 
was added to the daidzein suspension and the final suspension was administered orally (10 mg 
kg−1 of daidzein) with a blunt needle via the esophagus into the stomach. Subsequently, blood 
samples (200 μL) were collected into heparinized micro-centrifuge tubes (100 IU mL−1 blood) 
from the caudal vein at 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6 and 8 h respectively. Blood samples 
were centrifuged for 5 min at 5,000g and the daidzein concentrations in the plasma were 
determined by LC. The area under the plasma concentration versus time curve (AUC) from time 
zero to final sampling time (12 h) was calculated by the linear trapezoidal rule. The peak plasma 
concentration (C max) and the time to reach the peak plasma concentration (T max) were observed 
from the experimental data.  
 
100 μL plasma was mixed with 200 μL acetonitrile in an Eppendorf tube. The tubes were 
vortexed for 1 min and centrifuged at 5,000g for 10 min, and 20 μL of the resulting supernatant 
was injected into the LC system.  
 
Standard Solutions for Linearity Testing  
Blank plasma was prepared from heparinized whole-blood samples collected from rats and 
stored at −20 °C. After thawing, stock solution of daidzein was added to yield final 
concentrations of 20, 50, 100, 200, 500 and 800 ng mL−1. The samples were then prepared for 
analysis as described above.  
 
Stability  
The stability of daidzein was assessed in spiked plasma samples stored at −20 °C for 1 month 
and at ambient temperature for at least 12 h. The stability of stock solutions stored at −20 °C was 
determined for up to 1 month by injecting appropriate dilutions in methanol on day 1, 15 and 30 
and comparing their peak areas with fresh stock solution prepared on the day of analysis. 
Samples were considered to be stable, if the assay values were within the acceptable limits of 
accuracy and precision, the percent deviation from the nominal concentration (accuracy) and the 
relative standard deviation must be ±20% and less than 20%, respectively.  
 
Selectivity  
Control rat plasma was assessed by the procedure as described above and compared with plasma 
samples to evaluate the selectivity of the method.  
 
Precision and Accuracy  
The precision and accuracy of the method were examined by adding known amounts of daidzein 
to pool plasma (quality control samples). For intra-day precision and accuracy of daidzein 
concentration and retention time, five replicate quality control samples at each concentration 
were assayed on the same day. The inter-day precision and accuracy were evaluated on three 
different days.  
 
Limit of Quantification (LOQ) and Recovery  
The limit of quantification (LOQ, S/N = 10) was determined by establishing the minimum 
concentration of analyte in plasma that could be quantified with acceptable accuracy and 
precision under the stated experimental conditions. The absolute recovery was calculated for 
three different concentrations of daidzein (20, 100 and 500 ng mL−1) as the mean (±SD) of three 
samples by comparing peak areas of directly injected analytes solutions with peak areas of 
extracted plasma samples.  
 
Statistical Analysis  
Statistical evaluations were performed by Student t-test of the paired observations to analyze the 
different concentrations of daidzein. P values <0.05 were considered to indicate significant 
differences. Data are expressed as means ±SD (n = 3).  
 
RESULTS 
Method Validation  
Under the chromatographic conditions described, daidzein peaks were well resolved in standard 
mixtures and endogenous plasma components did not give any interfering peaks. Figure 2 shows 
typical chromatograms of blank plasma in comparison with spiked samples analyzed for a 
pharmacokinetic study. The average retention time of daidzein was 6.8 min. The calibration 
curve for the determination of daidzein in plasma was linear over the range 20–800 ng mL−1. The 
linearity of this method was statistically confirmed. The following regression equations were 
obtained: A = 164.9C (ng mL−1) + 60.5, r = 0.9998. The absolute analytical recovery of daidzein, 
determined at three concentrations (20, 100 and 500 ng mL−1), were 89.8 ± 4.8, 91.3 ± 2.8 and 
95.4 ± 1.7% (n = 3). The limit of quantification (LOQ), as previously defined, was 15 ng mL−1. 
This is sensitive enough for drug monitoring and other purposes such as pharmacokinetic studies. 
We assessed the precision of the method by repeated analysis of plasma specimens containing 
known concentrations of daidzein; the intra-day RSD values of daidzein concentration were less 
than 4.6%, inter-day RSD values were less than 6.1%. We also assessed the reproducibility of 
the retention time by repeated analysis of plasma specimens containing daidzein, the intra-day 
RSD values of retention time were less than 1.0%, inter-day RSD values were less than 1.5%, 
which was acceptable for the routine measurement. Stability was determined for spiked plasma 
samples under the conditions as previously described. The results showed that the samples were 
stable under the conditions used.  
 
 
Figure 2: Chromatograms of a blank plasma, b blank plasma spiked with daidzein, c plasma sample. Peak 1 
daidzein (t R = 6.8 min)  
 
 
Absorption Characteristics of Daidzein Across the Intestinal Membranes  
Effect of pH on the Absorption of Daidzein. Transepithelial absorption of daidzein across the 
rat intestinal membrane was examined at pH 5.5, 6.0, 6.5, 7.0 and 7.4; values at pH 5.5 were 
used as controls. The studies were performed at a concentration of 20 μg mL−1 of daidzein. 
Effect of pH on transepithelial absorption is shown in Figure 3. It was found that pH dependence 
was observed for the absorptive of daidzein in the pH range of 5.5–7.4. The absorption P app 
(mucosal to serosal) of daidzein changed significantly over this pH range.  
 
 
 
Figure 3: Effects of pH on the absorption of daidzein across the rat intestinal membrane. Data are the mean ± SD 
from at least three determinations. *P < 0.05 from the pH 5.5 control with Dunnett t-test  
 
 
Effect of Absorption Enhancers on the Absorption of Daidzein. Borneol as an absorption 
enhancer was added to the daidzein solution, to a final concentration of borneol of 20 μg mL−1. 
Figure 4 shows the time course of absorption (mucosal to serosal) of daidzein across the rat 
intestinal membrane with and without borneol. Addition of borneol to mucosal side increasd the 
absorption of daidzein significantly.  
 
 
 
Figure 4: Time course of absorptive of daidzein(-▲-) and effect of borneol on the absorption of daidzein(-■-) 
across the rat intestinal membrane. Data are the mean ± SD from at least three determinations  
 
 
Bioavailability Study and Pharmacokinetic Analysis  
Plasma concentration-time profiles of daidzein given orally as a suspension (10 mg kg−1 of 
daidzein) alone or in combination with borneol (10 mg kg−1 of borneol), in Sprague–Dawley rats 
are given in Figure 5. A significant increase in daidzein plasma concentration was observed after 
oral administration with borneol.  
 
Figure 5: Plasma concentration–time profiles of daidzein in rats after oral administration of daidzein(10 mg mL−1) 
alone(-■-) and in combination with borneol(-▲-). Data are the means ± SD (n = 4)  
 
 
Table 1 shows the pharmacokinetic parameters of daidzein, given alone or in combination with 
borneol. C max of daidzein/borneol was 1.9 times higher than when daidzein was administered 
alone. Relative bioavailability of daidzein/borneol was 1.5 times higher compared to daidzein 
suspension. 
 
Table 1: Pharmacokinetic parameters of daidzein after oral (10 mg kg−1) administration in rats  
Administration C max (ng mL−1)  T max (h)  AUC0–12 (ng h mL−1)  
Oral daidzein only 128.57 ± 27.64 0.33 ± 0.04 331.27 ± 115.76 
Oral daidzein + borneol 249.78 ± 24.24* 0.25 ± 0.07 NS 512.03 ± 146.53* 
Each value represents the mean ± SD of four experiments. NS not significantly different, *P < 0.05, compared with control  
 
CONCLUSION 
Daidzein preparations and nutritional supplements containing daidzein are widely consumed for 
their potential health effects. However, the oral bioavailability of daidzein is very poor, which 
limits its beneficial effects [30–33]. We investigated the absorption characteristics of daidzein 
across the intestinal membranes, with and without borneol as an absorption enhancer.  
 
The method of analysis developed by us is well suited for routine application in the clinical 
laboratory because of its speed and the simple extraction procedure required which only involves 
protein precipitation.  
 
Many drugs are well absorbed by the gastrointestinal tract. The small intestine represents the 
principal site of drug absorption. In this study, we evaluated the absorption characteristics across 
the intestinal membranes of daidzein. It was found that pH dependence of absorption was 
observed in the pH range of 5.5–7.4. The accumulation absorption amount and P app of the 
mucosal to serosal was highest at pH 7.4. One interpretation for this result is that daidzein has a 
phenolic hydroxyl group, which is weakly acid, thus higher pH may increase its solubility.  
 
Borneol was applied to the present study to improve daidzein absorption in the intestine. The 
results indicated that borneol enhanced the bioavailability of daidzein by enhancing its 
permeability.  
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